Literature DB >> 23667214

Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial.

Daniel Weintraub1, John E Duda, Kimberly Carlson, Ping Luo, Oren Sagher, Matthew Stern, Kenneth A Follett, Domenic Reda, Frances M Weaver.   

Abstract

BACKGROUND: The risk of suicide behaviours post-deep brain stimulation (DBS) surgery in Parkinson's disease (PD) remains controversial. We assessed if suicide ideation and behaviours are more common in PD patients (1) randomised to DBS surgery versus best medical therapy (BMT); and (2) randomised to subthalamic nucleus (STN) versus globus pallidus interna (GPi) DBS surgery.
METHODS: In Phase 1 of the Veterans Affairs CSP 468 study, 255 PD patients were randomised to DBS surgery (n=121) or 6 months of BMT (n=134). For Phase 2, a total of 299 patients were randomised to STN (n=147) or GPi (n=152) DBS surgery. Patients were assessed serially with the Unified Parkinson's Disease Rating Scale Part I depression item, which queries for suicide ideation; additionally, both suicide behaviour adverse event data and proxy symptoms of increased suicide risk from the Parkinson's Disease Questionnaire (PDQ-39) and the Short Form Health Survey (SF-36) were collected.
RESULTS: In Phase 1, no suicide behaviours were reported, and new-onset suicide ideation was rare (1.9% for DBS vs 0.9% for BMT; Fisher's exact p=0.61). Proxy symptoms of relevance to suicide ideation were similar in the two groups. Rates of suicide ideation at 6 months were similar for patients randomised to STN versus GPi DBS (1.5% vs 0.7%; Fisher's exact p=0.61), but several proxy symptoms were worse in the STN group.
CONCLUSIONS: Results from the randomised, controlled phase of a DBS surgery study in PD patients do not support a direct association between DBS surgery and an increased risk for suicide ideation and behaviours.

Entities:  

Keywords:  BEHAVIOURAL DISORDER; PARKINSON'S DISEASE; SURGERY

Mesh:

Year:  2013        PMID: 23667214      PMCID: PMC4594869          DOI: 10.1136/jnnp-2012-304396

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  Parkinson's disease, DBS and suicide: a role for serotonin?

Authors:  Yasin Temel; Sonny Tan; Veerle Visser-Vandewalle; Trevor Sharp
Journal:  Brain       Date:  2009-06-24       Impact factor: 13.501

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

Authors:  C Jenkinson; V Peto; R Fitzpatrick; R Greenhall; N Hyman
Journal:  Age Ageing       Date:  1995-11       Impact factor: 10.668

4.  Chronic medical problems and distressful thoughts of suicide in primary care patients: mitigating role of happiness.

Authors:  Jameson K Hirsch; Paul R Duberstein; Jürgen Unützer
Journal:  Int J Geriatr Psychiatry       Date:  2009-07       Impact factor: 3.485

5.  Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease.

Authors:  A Funkiewiez; C Ardouin; E Caputo; P Krack; V Fraix; H Klinger; S Chabardes; K Foote; A-L Benabid; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

6.  Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory.

Authors:  B E Levin; M M Llabre; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

Review 7.  The scientific and clinical basis for the treatment of Parkinson disease (2009).

Authors:  C Warren Olanow; Matthew B Stern; Kapil Sethi
Journal:  Neurology       Date:  2009-05-26       Impact factor: 9.910

8.  A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease.

Authors:  Valerie Voon; Paul Krack; Anthony E Lang; Andres M Lozano; Kathy Dujardin; Michael Schüpbach; James D'Ambrosia; Stephane Thobois; Filippo Tamma; Jan Herzog; Johannes D Speelman; Johan Samanta; Cynthia Kubu; Helene Rossignol; Yu-Yan Poon; Jean A Saint-Cyr; Claire Ardouin; Elena Moro
Journal:  Brain       Date:  2008-10       Impact factor: 13.501

9.  Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Authors:  Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang
Journal:  JAMA       Date:  2009-01-07       Impact factor: 56.272

10.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Authors:  Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

View more
  42 in total

1.  On-period unified Parkinson's disease rating scale before surgery correlates with differences in outcomes between pallidal and subthalamic stimulation: a meta-analysis.

Authors:  Wataru Sako; Nagahisa Murakami; Yoshimichi Miyazaki; Yuishin Izumi; Ryuji Kaji
Journal:  Neurol Sci       Date:  2015-09-03       Impact factor: 3.307

Review 2.  Deep Brain Stimulation Emergencies: How the New Technologies Could Modify the Current Scenario.

Authors:  Giovanni Cossu; Mariachiara Sensi
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

Review 3.  Psychiatric and Cognitive Effects of Deep Brain Stimulation for Parkinson's Disease.

Authors:  Adam Nassery; Christina A Palmese; Harini Sarva; Mark Groves; Joan Miravite; Brian Harris Kopell
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

4.  Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials.

Authors:  L Perestelo-Pérez; A Rivero-Santana; J Pérez-Ramos; P Serrano-Pérez; J Panetta; P Hilarion
Journal:  J Neurol       Date:  2014-02-02       Impact factor: 4.849

Review 5.  Deep brain stimulation for psychiatric diseases: what are the risks?

Authors:  Christian Saleh; Denys Fontaine
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

6.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01

7.  Hospital care for mental health and substance abuse conditions in Parkinson's disease.

Authors:  Allison W Willis; Dylan P Thibault; Peter N Schmidt; E Ray Dorsey; Daniel Weintraub
Journal:  Mov Disord       Date:  2016-12       Impact factor: 10.338

Review 8.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

Review 9.  Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches.

Authors:  Aparna Wagle Shukla; Michael Scott Okun
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.